» Articles » PMID: 14722897

Strong Cell-mediated Immune Responses Are Associated with the Maintenance of Low-level Viremia in Antiretroviral-treated Individuals with Drug-resistant Human Immunodeficiency Virus Type 1

Overview
Journal J Infect Dis
Date 2004 Jan 15
PMID 14722897
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Antiretroviral (ARV)-treated patients often maintain low to moderate levels of viremia, despite the emergence of drug-resistant human immunodeficiency virus (HIV). We studied host and viral factors that may contribute to the control of viral replication in a cohort of 189 adults. Among ARV-treated patients with detectable viremia, there was a bell-shaped relationship between Gag-specific CD4+ T cell responses and viremia, with the highest cellular immune responses observed in patients with plasma HIV RNA levels of 1000-10,000 copies/mL. In contrast, there was a negative association between Gag-specific CD4+ T cell responses and viremia among ARV-untreated individuals with wild-type HIV. Strong cellular immune responses among individuals with drug-resistant HIV predicted subsequent lack of virological progression. Finally, there was a positive correlation between replicative capacity and viremia. Collectively, these data suggest that the selection of drug-resistance mutations may reduce the pathogenic potential of HIV, which leads to a balanced state of enhanced cellular immunity and low-level viremia.

Citing Articles

Prevention, treatment and cure of HIV infection.

Landovitz R, Scott H, Deeks S Nat Rev Microbiol. 2023; 21(10):657-670.

PMID: 37344551 DOI: 10.1038/s41579-023-00914-1.


Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.

Podrazil M, Taborska P, Stakheev D, Rataj M, Lastovicka J, Vlachova A Front Immunol. 2022; 13:892277.

PMID: 35669765 PMC: 9163958. DOI: 10.3389/fimmu.2022.892277.


CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.

Costiniuk C, Singer J, Langlois M, Kulic I, Needham J, Burchell A BMJ Open. 2021; 11(12):e054208.

PMID: 34916326 PMC: 8678543. DOI: 10.1136/bmjopen-2021-054208.


SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors.

Taborska P, Lastovicka J, Stakheev D, Strizova Z, Bartunkova J, Smrz D Immun Inflamm Dis. 2021; 9(4):1452-1467.

PMID: 34314576 PMC: 8427053. DOI: 10.1002/iid3.496.


Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1.

Peluso M, Thanh C, Prator C, Hogan L, Arechiga V, Stephenson S J Virus Erad. 2020; 6(1):19-26.

PMID: 32175087 PMC: 7043898.